RE: Suspension22 Sep 2022 21:29
Biosynex acquires Italian Bigix Pharma information provided by AOF•09/22/2022 at 08:57 (AOF) – Biosynex has signed an agreement to acquire 100% of the capital of the Italian company Bigix Pharma from its founding partners. The finalization of this acquisition will take place in the coming days, after completion of the formalities required in Italy. Bigix Pharma already has a customer portfolio of more than 5,000 pharmacies, approached by its sales force, made up of more than 40 independent sales agents. Bigix Pharma distributes various product lines in the medical equipment segment and achieved in 2021 a turnover of approximately 2.9 million euros. With this acquisition, Biosynex will be able to penetrate the Italian Pharmacy market, which represents more than 20,000 points of sale, and launch its own ranges of self-tests, thermometers, mosquito repellents, hot water bottles under Disney license and other products. catalog headlights. After the opening of two subsidiaries in Switzerland in 2020 and in Benelux in June 2022, Bigix Pharma becomes the 3rd European subsidiary of Biosynex in Italy, thus strengthening the European network of pharmacies and parapharmacies with more than 50,000 points of sale visited directly by group sales forces. AOF - LEARN MORE An inevitable race for new blockbusters The patent for Merck's star product, the cancer drug Keytruda, which accounts for more than 35% of its sales, expires in 2028. Despite the loss, since 2019, of the patents for its three star products (Avastin, Herceptine, Rituxan) Roche was able to renew its portfolio by bringing new molecules to market. However, the discovery and launch of new drugs are increasingly expensive. AstraZeneca spends about $6 billion a year on R&D in a pharmaceutical industry where the life of a patent only lasts ten to fifteen years. This leads laboratories to withdraw from certain activities. Thus J&J, Pfizer, GSK and, no doubt, Novartis soon prefer to refocus on specialty drugs and abandon any ancillary activity.
Google translate did the job!
Sign In
Follow the stocks
